Who are Zerbaxa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fetroja, Teflaro, Cefditoren Pivoxyl, Omnicef, Maxipime, Cedax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftolozane.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Zerbaxa — Competitive Intelligence Brief

Zerbaxa (CEFTOLOZANE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin Antibacterial. Area: Infectious Disease.

marketed Cephalosporin Antibacterial Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Zerbaxa (CEFTOLOZANE) — Cubist Pharms. Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Zerbaxa TARGET	CEFTOLOZANE	Cubist Pharms	marketed	Cephalosporin Antibacterial	2014-01-01
Fetroja	CEFIDEROCOL	Shionogi	marketed	Cephalosporin Antibacterial	2019-01-01
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	marketed	Cephalosporin Antibacterial	2010-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	marketed	Cephalosporin Antibacterial	2001-01-01
Omnicef	CEFDINIR		marketed	Cephalosporin Antibacterial [EPC]	1997-01-01
Maxipime	CEFEPIME	Baxter	marketed	Cephalosporin Antibacterial	1996-01-01
Cedax	ceftibuten	Burke Therap	marketed	Cephalosporin Antibacterial	1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-15 — Zerbaxa · 7129232 · US
2032-09-07 — Zerbaxa · 10028963 · US
2032-09-07 — Zerbaxa · 9724353 · US
2032-09-27 — Zerbaxa · 8476425 · US
2032-09-27 — Zerbaxa · 8685957 · US
2034-03-14 — Zerbaxa · 10420841 · US
2034-03-14 — Zerbaxa · 11278622 · US
2034-03-14 — Zerbaxa · 8968753 · US
2034-03-14 — Zerbaxa · 9320740 · US
2034-03-14 — Zerbaxa · 9872906 · US
2034-05-28 — Zerbaxa · 8906898 · US
2034-09-09 — Zerbaxa · 10376496 · US
2034-09-09 — Zerbaxa · 10933053 · US
2035-08-14 — Zerbaxa · 10125149 · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zerbaxa — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftolozane. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab